关节内素脱乙酶抑制剂微载体输送以减少骨关节炎
Jing Ye1,2, Ronghui Deng1,2, Xinjie Wang1,2
1Sports Medicine Department, Beijing Key Laboratory of Sports Injuries, Peking University Third Hospital, No. 49 North Garden Road, Haidian District, Beijing 100191, China.
Nano letters
|November 27, 2023
概括
基因组脱乙酶抑制剂 (HDACi) 在骨关节炎治疗中表现有前途. 囊括在多 (d,l-乳-co-glycolide) 微囊中的奇胺有效地抑制了软骨的破坏和退化,提供了一个新的治疗策略.
科学领域:
- 生物医学工程 生物医学工程
- 药理学 药理学是指药理学的学科.
- 骨关节炎研究 骨关节炎研究
背景情况:
- 基斯脱乙酶抑制剂 (HDACi) 是对T细胞淋巴瘤的确立治疗方法.
- 在骨关节炎 (OA) 中HDACi的治疗潜力仍然在很大程度上未被探索.
- 开发有效的药物输送系统对于OA治疗至关重要.
研究的目的:
- 开发一种微载体系统,用于在骨关节炎治疗中持续输送奇胺.
- 为了评估充满奇达胺的微囊在预防软骨退化方面的有效性.
- 调查奇达米德在OA中的作用机制.
主要方法:
- 聚,d,l-乳-co-glycolide) (PLGA) 微囊是使用乳液溶剂蒸发方法制造的.
- 奇胺被封装在PLGA微囊中,以实现受控和持续释放.
- 使用紫外线光谱和扫描电子显微镜证实了封装效率.
- 通过评估Tnnt3的抑制和免疫刺激以及对软骨破坏的保护来评估治疗效果.
主要成果:
- PLGA微囊表现出调节和持续释放的特征,最初的突发释放最小.
- 在PLGA微囊中成功封装奇达胺被证实.
- 奇胺治疗抑制了软骨的破坏,并防止了关节软骨的退化.
- 该机制涉及Tnnt3的抑制和免疫刺激.
结论:
- 含有奇胺的PLGA微囊代表了对骨关节炎的有前途,变革性的治疗策略.
- 这种方法可以缓解症状,并保护OA患者免受软骨退化.
- 微载体系统增强了奇达米德在治疗骨关节炎的疗效.
相关概念视频
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...